echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > AstraZeneta will sign a PARPi research and development agreement with Theragnostics

    AstraZeneta will sign a PARPi research and development agreement with Theragnostics

    • Last Update: 2021-03-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Theragnostics announced that it has signed an intellectual property licensing agreement with AstraZeneta that will enable the company to operate globally in selected radionuclide-labeled PARPi diagnostics.
    The agreement strengthens Theragnostics' intellectual property posture and enables the company to accelerate the development of its rPARPi treatment and diagnostic portfolio.
    The company is developing molecular radiotherapy for imaging and treating a variety of cancers, and the platform is able to develop PARPi-based molecular radiotherapy for imaging and treating cancer.
    It uses radioatomic modification of PARPi drug molecules to produce radionuclide PARPi (rPARPi), which can be used for diagnostic use of PARP imaging in cancer patients, or radioisotopes can be used to deliver therapeutic doses of radioisotope cells to tumors, providing the potential for molecular targeted radiation to hit and kill tumor cells while avoiding damage to healthy cells and associated side effects.
    Currently, at least four approved traditional drugs, PARPi, have been approved in several markets in recent months for new and expanded allergies.
    Gareth Smith, chief operating officer of Theragnostics, said, "The company believes that radionuclide PARPi therapy will play a role independently of mutations in DNA (such as BRCA1/BRCA2) associated with PARPi activity enhancement and will avoid the development of therapeutic resistance." As a result, the number of patients benefiting from PARPi treatment may be significantly expanded.PARP inhibitors are a new class of tumor drugs that block an enzyme (poly (ADP-UC) polymerase, the response of cancer cells to DNA damage, caused by endogenous and chemotherapy treatments. (cyy123.com)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.